Research programme: autoimmune disorder therapeutics - Ginkgo Bioworks/Microba Life Sciences
Latest Information Update: 06 Sep 2023
At a glance
- Originator Microba Life Sciences
- Developer Ginkgo Pharma; Microba Life Sciences
- Class Antirheumatics; Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Autoimmune disorders; Psoriatic arthritis; Systemic lupus erythematosus